Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-1/endoglin pathway in endothelial cells

Summary

Recurrent epistaxis is the most frequent clinical manifestation of hereditary haemorrhagic telangiectasia (HHT). Its treatment is difficult. Our objective was to assess the use of tranexamic acid (TA), an antifibrinolytic drug, for the treatment of epistaxis in HHT patients and to investigate in vitro the effects of TA over endoglin and ALK-1 expression and activity in endothelial cells. A prospective study was carried out on patients with epistaxis treated with oral TA in the HHT Unit of Sierrallana Hospital (Cantabria, Spain). Primary cultures of endothelial cells were treated with TA to measure the levels of endoglin and ALK-1 at the cell surface by flow cytometry. RNA levels were also measured by real-time PCR, and the transcriptional effects ofTA on reporters for endoglin, ALK-1 and the endoglin/ALK-1 TGF-beta pathway were assessed. The results showed that the fourteen HHT patients treated orally withTA improved, and the frequency and severity of their epistaxis were decreased. No complications derived from the treatment were observed. Cultured endothelial cells incubated with TA exhibited increased levels of endoglin and ALK-1 at the protein and mRNA levels, enhanced TGF-β signaling, and improved endothelial cell functions like tubulogenesis and migration. In summary, oral administration of TA proved beneficial for epistaxis treatment in selected patients with HHT. In addition to its already reported antifibrinolytic effects, TA stimulates the expression ofALK-1 and endoglin,as well as the activity of the ALK-1/endoglin pathway.

Keywords

Endothelial cells - HHT - endoglin - ALK-1 - tranexamic acid - fibrinolysis

• References

• 1 Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-729.
• 2 Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999; 245: 31-39.
• 3 Jessurun GA, Kamphuis DJ, van der Zande FH. et al. Cerebral arteriovenous malformations in The Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clin Neurol Neurosurg 1993; 95: 193-198.
• 4 Morales Angulo C, Megia Lopez R, del Valle Zapico A. et al. Rendu-Osler-Weber disease (hereditary hemorrhagic telangiectasia). Report of 30 cases. Acta Otorrinolaringol Esp 1997; 48: 625-629.
• 5 McAllister KA, Grogg KM, Johnson DW. et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-351.
• 6 Johnson DW, Berg JN, Baldwin MA. et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189-195.
• 7 Gallione CJ, Pasyk KA, Boon LM. et al. A gene for familial venous malformations maps to chromosome 9p in a second large kindred. J Med Genet 1995; 32: 197-199.
• 8 Cole SG, Begbie ME, Wallace GM. et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005; 42: 577-582.
• 9 Plauchu H, de Chadarevian JP, Bideau A. et al. Agerelated clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297.
• 10 Perez del Molino A, Zarrabeitia R, Fernandez A. Hereditary hemorrhagic telangiectasia. Med Clin (Barc) 2005; 124: 583-587.
• 11 Morales-Angulo C, del Valle-Zapico A. Hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1998; 119: 293.
• 12 Os AA, Friedman CM, White Jr RI. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991; 101: 977-980.
• 13 Guttmacher AE, Marchuk DA, White Jr RI. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333: 918-924.
• 14 Morais D, Ramirez B, Santos J. Local sclerosing treatment with etoxiesclerol in ORL disease: Rendu- Osler disease, granuloma, angioma. Acta Otorrinolaringol Esp 2002; 53: 658-661.
• 15 Ramirez B, Morais D, Condado MA. et al. A new sclerosant for the treatment of Rendu-Osler-Weber disease. Acta Otorrinolaringol Esp 2000; 51: 36-39.
• 16 Escalante A, Pinzon A, Belloso E. et al. Cobalt therapy in the treatment of Osler-Rendu disease. Apropos of two cases. Acta Otorrinolaringol Esp 1988; 39: 57-59.
• 17 Urpegui AM, Abenia JM, Morandeira MJ. et al. Experimental microsurgery of the facial nerve: end-toend suture versus approximated ends wrapped with masseter muscle aponeurosis. Acta Otorrinolaringol Esp 1998; 49: 107-110.
• 18 Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994; 330: 1789-1790.
• 19 Annichino-Bizzacchi JM, Facchini RM, Torresan MZ. et al. Hereditary hemorrhagic telangiectasia response to aminocaproic acid treatment. Thromb Res 1999; 96: 73-76.
• 20 Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 926.
• 21 Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001; 161: 767.
• 22 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-253.
• 23 Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids. Biochim Biophys Acta 1975; 393: 55-65.
• 24 Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981; 673: 75-85.
• 25 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-261.
• 26 Shovlin CL, Guttmacher AE, Buscarini E. et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67.
• 27 Sadick H, Naim R, Oulmi J. et al. Plasma surgery and topical estriol: effects on the nasal mucosa and long-term results in patients with Osler's disease. Otolaryngol Head Neck Surg 2003; 129: 233-238.
• 28 Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R. et al. Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res 2005; 68: 235-248.
• 29 Sanz-Rodriguez F, Fernandez-L A, Zarrabeitia R. et al. Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: Deficient endoglin up-regulation in activated monocytes. Clin Chem 2004; 50: 2003-2011.
• 30 Rius C, Smith JD, Almendro N. et al. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 1998; 92: 4677-4690.
• 31 Botella LM, Sanchez-Elsner T, Rius C. et al. Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation. J Biol Chem 2001; 276: 34486-34494.
• 32 Blanco FJ, Santibanez JF, Guerrero-Esteo M. et al. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005; 204: 574-584.
• 33 Perez del Molino A, Zarrabeitia R, Fernandez A. et al. Efficacy of tranexamic acid in a patient with hereditary hemorrhagic telangiectasia and massive epistaxis. Med Clin (Barc) 2004; 123: 118-119.
• 34 Lebrin F GM, Jonker L, Carvalho RL. et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ ALK-1 signal transduction. EMBO J 2004; 23: 4018-4028.
• 35 Byahatti SV, Rebeiz EE, Shapshay SM. Hereditary hemorrhagic telangiectasia: what the otolaryngologist should know. Am J Rhinol 1997; 11: 55-62.
• 36 Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol 1973; 107: 571-573.
• 37 Watanabe M, Hanawa S, Morishima T. Fibrinolytic activity in cutaneous lesions of hereditary hemorrhagic telangiectasia. Nippon Hifuka Gakkai Zasshi 1985; 95: 11-16.
• 38 Shovlin CL, Hughes JM, Scott J. et al. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 1997; 61: 68-79.
• 39 Gallione CJ, Klaus DJ, Yeh EY. et al. Mutation and expression analysis of the endoglin gene in hereditary hemorrhagic telangiectasia reveals null alleles. Hum Mutat 1998; 11: 286-294.
• 40 Abdalla SA, Geisthoff UW, Bonneau D. et al. Visceral manifestations in hereditary haemorrhagic telangiectasia type 2. J Med Genet 2003; 40: 494-502.
• 41 Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110.
• 42 Lebrin F, Deckers M, Bertolino P. et al. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65: 599-608.
• 43 Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932-939. Review.